retatrutide cardiovascular effects ESC 2024: improves lipid and risk profile in Phase II trial Diagram showing the mechanism of

Both studies found that people who took GLP-1s had worse vision outcomes than those who did not

Kahn says in some instances the popularity of peptides has outpaced the science, but she will prescribe them as an "adjunct" therapy if she thinks it's appropriate

TalalayP.De LongM

These two conditions are closely interrelated, with DM representing a significant risk factor for CVD due to factors such as obesity, hypercholesterolemia, atherosclerosis, microcirculation disorders, and hypertension [1, 2]

Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial